Skip to main content
Top
Published in: Breast Cancer Research 5/2013

Open Access 01-10-2013 | Research article

Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series

Authors: Valerie A McCormack, Maureen Joffe, Eunice van den Berg, Nadine Broeze, Isabel dos Santos Silva, Isabelle Romieu, Judith S Jacobson, Alfred I Neugut, Joachim Schüz, Herbert Cubasch

Published in: Breast Cancer Research | Issue 5/2013

Login to get access

Abstract

Introduction

Estimates of the proportion of estrogen receptor negative (ERN) and triple-negative (TRN) breast cancer from sub-Saharan Africa are variable and include high values. Large studies of receptor status conducted on non-archival tissue are lacking from this region.

Methods

We identified 1218 consecutive women (91% black) diagnosed with invasive breast cancer from 2006–2012 at a public hospital in Soweto, South Africa. Immunohistochemistry based ER, progesterone receptor (PR) and human epidermal factor 2 (HER2) receptors were assessed at diagnosis on pre-treatment biopsy specimens. Mutually adjusted associations of receptor status with stage, age, and race were examined using risk ratios (RRs). ER status was compared with age-stratified US Surveillance Epidemiology and End Results program (SEER) data.

Results

35% (95% confidence interval (CI): 32–38) of tumors were ERN, 47% (45–52) PRN, 26% (23–29) HER2P and 21% (18–23) TRN. Later stage tumors were more likely to be ERN and PRN (RRs 1.9 (1.1-2.9) and 2.0 (1.3-3.1) for stage III vs. I) but were not strongly associated with HER2 status. Age was not strongly associated with ER or PR status, but older women were less likely to have HER2P tumors (RR, 0.95 (0.92-0.99) per 5 years). During the study, stage III + IV tumors decreased from 66% to 46%. In black women the percentage of ERN (37% (34–40)) and PRN tumors (48% (45–52)) was higher than in non-black patients (22% (14–31) and 34% (25–44), respectively, P = 0.004 and P = 0.02), which remained after age and stage adjustment. Age-specific ERN proportions in black South African women were similar to those of US black women, especially for women diagnosed over age 50.

Conclusion

Although a greater proportion of black than non-black South African women had ER-negative or TRN breast cancer, in all racial groups in this study breast cancer was predominantly ER-positive and was being diagnosed at earlier stages over time. These observations provide initial indications that late-stage aggressive breast cancers may not be an inherent feature of the breast cancer burden across Africa.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de RM, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158/1078-0432.CCR-04-0220.CrossRefPubMed Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de RM, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374. 10.1158/1078-0432.CCR-04-0220.CrossRefPubMed
2.
go back to reference Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
3.
go back to reference Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE: Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008, 110: 183-188. 10.1007/s10549-007-9694-5.CrossRefPubMed Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE: Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008, 110: 183-188. 10.1007/s10549-007-9694-5.CrossRefPubMed
4.
go back to reference Awadelkarim KD, Arizzi C, Elamin EO, Hamad HM, De BP, Mekki SO, Osman I, Biunno I, Elwali NE, Mariani-Costantini R, Barberis MC: Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. Histopathology. 2008, 52: 445-456. 10.1111/j.1365-2559.2008.02966.x.CrossRefPubMed Awadelkarim KD, Arizzi C, Elamin EO, Hamad HM, De BP, Mekki SO, Osman I, Biunno I, Elwali NE, Mariani-Costantini R, Barberis MC: Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. Histopathology. 2008, 52: 445-456. 10.1111/j.1365-2559.2008.02966.x.CrossRefPubMed
5.
go back to reference Basro S, Apffelstaedt JP: Breast cancer in young women in a limited-resource environment. World J Surg. 2010, 34: 1427-1433. 10.1007/s00268-009-0299-5.CrossRefPubMed Basro S, Apffelstaedt JP: Breast cancer in young women in a limited-resource environment. World J Surg. 2010, 34: 1427-1433. 10.1007/s00268-009-0299-5.CrossRefPubMed
6.
go back to reference Bird PA, Hill AG, Houssami N: Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?. Ann Surg Oncol. 2008, 15: 1983-1988. 10.1245/s10434-008-9900-7.CrossRefPubMed Bird PA, Hill AG, Houssami N: Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?. Ann Surg Oncol. 2008, 15: 1983-1988. 10.1245/s10434-008-9900-7.CrossRefPubMed
7.
go back to reference Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI: Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009, 27: 4515-4521. 10.1200/JCO.2008.19.6873.CrossRefPubMedPubMedCentral Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI: Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009, 27: 4515-4521. 10.1200/JCO.2008.19.6873.CrossRefPubMedPubMedCentral
8.
go back to reference Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y: Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res. 2002, 22: 3005-3012.PubMed Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y: Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res. 2002, 22: 3005-3012.PubMed
9.
go back to reference Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman M, Quayson SE, Zarbo R, Wicha M, Newman L: African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. 2010, 116: 4926-4932. 10.1002/cncr.25276.CrossRefPubMedPubMedCentral Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman M, Quayson SE, Zarbo R, Wicha M, Newman L: African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. 2010, 116: 4926-4932. 10.1002/cncr.25276.CrossRefPubMedPubMedCentral
10.
go back to reference Anderson WF, Katki HA, Rosenberg PS: Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst. 2011, 103: 1397-1402. 10.1093/jnci/djr257.CrossRefPubMedPubMedCentral Anderson WF, Katki HA, Rosenberg PS: Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst. 2011, 103: 1397-1402. 10.1093/jnci/djr257.CrossRefPubMedPubMedCentral
11.
go back to reference Jemal A, Fedewa SA: Is the prevalence of ER-negative breast cancer in the US higher among Africa-born than US-born black women?. Breast Cancer Res Treat. 2012, 135: 867-873. 10.1007/s10549-012-2214-2.CrossRefPubMed Jemal A, Fedewa SA: Is the prevalence of ER-negative breast cancer in the US higher among Africa-born than US-born black women?. Breast Cancer Res Treat. 2012, 135: 867-873. 10.1007/s10549-012-2214-2.CrossRefPubMed
12.
go back to reference Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG: Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008, 16: 513-520. 10.1097/PAI.0b013e31818a9d3a.CrossRefPubMed Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG: Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008, 16: 513-520. 10.1097/PAI.0b013e31818a9d3a.CrossRefPubMed
13.
go back to reference Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME: Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2004, 13: 667-672.PubMed Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME: Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2004, 13: 667-672.PubMed
14.
go back to reference Committee of Enquiry, Health Chapter: Policy Options for the Future Covering. Chapter 2: South Africa Health System: A Review. 2002, Department of Health, Republic of South Africa Committee of Enquiry, Health Chapter: Policy Options for the Future Covering. Chapter 2: South Africa Health System: A Review. 2002, Department of Health, Republic of South Africa
16.
go back to reference Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004, 5: 63-69. 10.3816/CBC.2004.n.011.CrossRefPubMed Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004, 5: 63-69. 10.3816/CBC.2004.n.011.CrossRefPubMed
17.
go back to reference Anderson WF, Luo S, Chatterjee N, Rosenberg PS, Matsuno RK, Goodman MT, Hernandez BY, Reichman M, Dolled-Filhart MP, O’Regan RM, Garcia-Closas M, Perou CM, Jatoi I, Cartun RW, Sherman ME: Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat. 2009, 113: 189-196. 10.1007/s10549-008-9918-3.CrossRefPubMed Anderson WF, Luo S, Chatterjee N, Rosenberg PS, Matsuno RK, Goodman MT, Hernandez BY, Reichman M, Dolled-Filhart MP, O’Regan RM, Garcia-Closas M, Perou CM, Jatoi I, Cartun RW, Sherman ME: Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat. 2009, 113: 189-196. 10.1007/s10549-008-9918-3.CrossRefPubMed
18.
go back to reference Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed
19.
go back to reference Surveillance Epidemiology and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence, SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973–2008 varying), Linked To County Attributes. 2010, Total U.S., 1969–2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch released April 2011 (updated 10/28/2011), based on the November 2010 submission. 2010. Ref Type: Report Surveillance Epidemiology and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence, SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973–2008 varying), Linked To County Attributes. 2010, Total U.S., 1969–2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch released April 2011 (updated 10/28/2011), based on the November 2010 submission. 2010. Ref Type: Report
20.
go back to reference Anderson WF, Chatterjee N, Ershler WB, Brawley OW: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002, 76: 27-36. 10.1023/A:1020299707510.CrossRefPubMed Anderson WF, Chatterjee N, Ershler WB, Brawley OW: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002, 76: 27-36. 10.1023/A:1020299707510.CrossRefPubMed
21.
go back to reference Anderson WF, Matsuno R: Breast cancer heterogeneity: a mixture of at least two main types?. J Natl Cancer Inst. 2006, 98: 948-951. 10.1093/jnci/djj295.CrossRefPubMed Anderson WF, Matsuno R: Breast cancer heterogeneity: a mixture of at least two main types?. J Natl Cancer Inst. 2006, 98: 948-951. 10.1093/jnci/djj295.CrossRefPubMed
22.
go back to reference Rubin D: Multiple Imputation for Nonresponse in Surveys. 1987, New York: WileyCrossRef Rubin D: Multiple Imputation for Nonresponse in Surveys. 1987, New York: WileyCrossRef
23.
go back to reference Gukas ID, Jennings BA, Mandong BM, Igun GO, Girling AC, Manasseh AN, Ugwu BT, Leinster SJ: Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr J Med. 2005, 24: 209-213.PubMed Gukas ID, Jennings BA, Mandong BM, Igun GO, Girling AC, Manasseh AN, Ugwu BT, Leinster SJ: Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr J Med. 2005, 24: 209-213.PubMed
24.
go back to reference Macfarlane R, Seal M, Speers C, Woods R, Masoudi H, Aparicio S, Chia SK: Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist. 2012, 17: 172-178. 10.1634/theoncologist.2011-0127.CrossRefPubMedPubMedCentral Macfarlane R, Seal M, Speers C, Woods R, Masoudi H, Aparicio S, Chia SK: Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist. 2012, 17: 172-178. 10.1634/theoncologist.2011-0127.CrossRefPubMedPubMedCentral
25.
go back to reference Moultrie TA, Timaeus IM: The South African fertility decline: evidence from two censuses and a demographic and health survey. Popul Stud (Cambridge). 2003, 57: 265-283. 10.1080/0032472032000137808.CrossRef Moultrie TA, Timaeus IM: The South African fertility decline: evidence from two censuses and a demographic and health survey. Popul Stud (Cambridge). 2003, 57: 265-283. 10.1080/0032472032000137808.CrossRef
26.
go back to reference Li CI, Daling JR, Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003, 21: 28-34. 10.1200/JCO.2003.03.088.CrossRefPubMed Li CI, Daling JR, Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003, 21: 28-34. 10.1200/JCO.2003.03.088.CrossRefPubMed
27.
go back to reference StatBite JNCI: StatBite: breast cancer: 5-year survival rates in U.S. for selected histologic types by stage. J Natl Cancer Inst. 2009, 101: 1303-Ref Type: ReportCrossRef StatBite JNCI: StatBite: breast cancer: 5-year survival rates in U.S. for selected histologic types by stage. J Natl Cancer Inst. 2009, 101: 1303-Ref Type: ReportCrossRef
28.
go back to reference Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E: Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 1999, 91: 2020-2028. 10.1093/jnci/91.23.2020.CrossRefPubMed Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E: Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 1999, 91: 2020-2028. 10.1093/jnci/91.23.2020.CrossRefPubMed
Metadata
Title
Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series
Authors
Valerie A McCormack
Maureen Joffe
Eunice van den Berg
Nadine Broeze
Isabel dos Santos Silva
Isabelle Romieu
Judith S Jacobson
Alfred I Neugut
Joachim Schüz
Herbert Cubasch
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3478

Other articles of this Issue 5/2013

Breast Cancer Research 5/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine